ALFA Filings
Every announcement, straight from the exchange
Every Beta Drugs earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Ltd. reports Q1-FY27 revenue of INR 1,255 Mn with 21.83% EBITDA margin. Diversifying beyond core oncology into IVF via Nivian acquisition.
Beta Drugs delivered record EBITDA but missed revenue guidance due to delayed export tenders and strategic withdrawal from the low-margin Platin segment.
Beta Drugs delivered FY26 revenue of ₹385 Cr with a shift towards high-margin branded oncology (36% of mix) and 22.57% EBITDA margin.